导管原位癌与术中部分乳腺照射:谁是最佳候选者?单中心系列长期结局
该单中心系列分析2000至2010年180例单纯导管原位癌(DCIS)患者,行象限切除联合21 Gy术中电子线部分乳腺照射(IOERT)。按ASTRO指南分为适合组84例与非适合组96例,全组5、7、10年同侧乳腺复发累积发生率分别为19%、21%、25%;适合组10年稳定于11%,非适合组由5年26%升至10年36%(P<0.0001)。结论认为复发率偏高,IOERT不应应用于临床实践。
要点
- 全组5、7、10年同侧乳腺复发累积发生率分别为19%、21%、25%。
- 适合组复发率10年稳定于11%,非适合组由5年26%升至10年36%(P<0.0001)。
- 加激素受体阳性且HER2无表达后适合组10年复发率降至4%并稳定。
核心结论
- 全组及按组同侧乳腺复发率均高,适合组DCIS需更严格标准才能获得可接受的局部控制。
- 由于上述顾虑,IOERT不应应用于临床实践。
研究设计与样本
- 单中心系列,2000至2010年纳入180例单纯DCIS患者,行象限切除联合21 Gy术中电子线部分乳腺照射(IOERT)。
- 按ASTRO指南适合定义(大小≤2.5 cm、分级1-2级、手术切缘≥3 mm)分为适合组84例与非适合组96例。
主要发现
- 全组5、7、10年同侧乳腺复发累积发生率分别为19%、21%、25%。
- 适合组同侧乳腺复发累积发生率历年保持11%,非适合组由5年26%升至10年36%(P<0.0001)。
- 在适合组选择中加上激素受体阳性且HER2无表达后,同侧乳腺复发累积发生率下降并稳定在10年4%。
- 全组无乳腺癌死亡,5年与10年总生存率分别为98%与96.5%,两组间无差异。
关键数值与推荐
- ASTRO指南适合定义:大小≤2.5 cm、分级1-2级、手术切缘≥3 mm。
- IOERT剂量为21 Gy。
临床怎么用
- 作者结论认为IOERT不应应用于临床实践。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To report the long-term outcome of a single institution series of pure ductal carcinoma in situ (DCIS) treated with accelerated partial irradiation using intraoperative electrons (IOERT). METHODS: From 2000 to 2010, 180 DCIS patients, treated with quadrantectomy and 21 Gy IOERT, were analyzed in terms of ipsilateral breast recurrences (IBRs) and survival outcomes by stratification in two subgroups. The low-risk group included patients who fulfilled the suitable definition according to American Society of Radiation Oncology (ASTRO) Guidelines (size ≤2.5 cm, grade 1-2 and surgical margins ≥3 mm) (Suitable), while the remaining ones formed the high-risk group (Non-Suitable). RESULTS: Eighty-four and 96 patients formed the Suitable and Non-Suitable groups, respectively. In the whole population, the cumulative incidence of IBR at 5, 7 and 10 years was 19%, 21%, and 25%, respectively. In the Suitable group, the cumulative incidence of IBR remained constant at 11% throughout the years, while in the Non-Suitable group increased from 26% at 5 years to 36% at 10 years (p < 0.0001). When hormonal positivity and HER2 absence of expression were added to the selection of the Suitable group, the cumulative incidence of IBR dropped and stabilized at 4% at 10 years. None died of breast cancer. In the whole population, 5-year and 10-year overall survival rate was 98% and 96.5%, respectively, without any difference between the two groups. CONCLUSIONS: The overall and by group IBR rates were high and stricter criteria are required for acceptable local control for Suitable DCIS. Because of the concerns raised, IOERT should not be used in clinical practice.
引用
- Leonardi MC, Corrao G, Frassoni S, et al. Ductal carcinoma in situ and intraoperative partial breast irradiation: Who are the best candidates? Long-term outcome of a single institution series. Radiother Oncol. 2019. PMID: 30935584. doi:10.1016/j.radonc.2018.12.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。